Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 03:53 am EST
Share
Orient EuroPharma Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 1,094.91 million compared to TWD 1,100.41 million a year ago. Net loss was TWD 34.77 million compared to TWD 187.49 million a year ago. Basic loss per share from continuing operations was TWD 0.4 compared to TWD 2.16 a year ago. Diluted loss per share from continuing operations was TWD 0.4 compared to TWD 2.16 a year ago.
For the nine months, sales was TWD 3,378.64 million compared to TWD 3,446.42 million a year ago. Net loss was TWD 196 million compared to TWD 261.21 million a year ago. Basic loss per share from continuing operations was TWD 2.26 compared to TWD 3.01 a year ago. Diluted loss per share from continuing operations was TWD 2.26 compared to TWD 3.01 a year ago.
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.
ORIENT EUROPHARMA CO., LTD. 
